Biological therapeutics for infection-relating disorders or conditions

Abstract

The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens.

Claims

1. A therapeutic product for treating a patient infected by an influenza virus, comprising: (a) an effective amount of N-acetylneuraminic acid; (b) an effective amount of N-acetylneuraminic acid methyl ester; and (c) at least one of serum or plasma, wherein combination of the effective amount of N-acetylneuraminic acid and the effective amount of N-acetylneuraminic acid methyl ester with at least one of serum or plasma reduces a rate of death caused by the influenza virus by at least about 70% compared to treatment with the at least one of serum or plasma alone, wherein the effective amount of N-acetylneuraminic acid comprises about 0.1 mg/kg to about 100 mg/kg of N-acetylneuraminic acid per kg body weight of a subject, wherein the effective amount of N-acetylneuraminic acid methyl ester comprises about 0.1 mg/kg to about 100 mg/kg of N-acetylneuraminic acid methyl ester per kg body weight of a subject, and wherein the serum or plasma is obtained from a healthy individual.

2. The therapeutic product of claim 1, wherein the product comprises about 0.1 mL to 1000 mL of serum or plasma.

3. The therapeutic product of claim 1, wherein the product comprises about 0.1 mg/mL to about 20 mg/mL or about 0.1 mg/g to about 20 mg/g of N-acetylneuraminic acid and about 0.1 mL to about 1000 mL of serum or plasma.

4. The therapeutic product of claim 1, wherein the product is in a solution, a lyophilized form, an injectable form, an infusion, or a form conjugated to a nano-particle.

5. The therapeutic product of claim 1, wherein the influenza virus is 2009 H1N1, B influenza, H5N1, H1N1, or H3N2.

6. The therapeutic product of claim 1, wherein the serum or plasma is obtained from more than one healthy individual.

7. The therapeutic product of claim 1, wherein the healthy individual is a human.

8. The therapeutic product of claim 1, wherein the patient is a human.

Description

BRIEF DESCRIPTION OF THE DRAWING

(1) FIG. 1 is a graphical representation of histology changes of lungs from the mouse pups delivered to the dams treated with human serum of healthy individuals (A) or the anti-09HIN1influenza virus serum (B). This data showed that antibodies induced by the 09H1N1 influenza vims are harmful to fetuses and newborns since it caused later fetal death (still birth) and neonatal death.

ADDITIONAL EMBODIMENTS

(2) Another embodiment of the present invention discloses therapeutic products comprising a vaccine or an inactivated pathogen for the treatment of a severe infection caused by antibodies induced during an infection; wherein the therapeutic vaccines or inactivated pathogens neutralize harmful antibodies induced during the infection.

(3) Another embodiment of the present invention discloses a method of administrating a therapeutic vaccine or an inactivated pathogen to a patient to prevent or treat the disorders or conditions caused by the antibodies against the vaccine or the pathogen; wherein the antibodies are induced during an infection; the therapeutic vaccines or inactivated pathogens neutralize harmful antibodies induced during the infection.

(4) Other embodiments besides the above may be articulated as well. The terms and expressions therefore serve only to describe the disclosure by example only and not to limit the disclosure. It is expected that others will perceive differences, which while differing from the foregoing, do not depart from the spirit and scope of the disclosure herein described and claimed. All patents, patent publications, and other references cited herein are incorporated herein by reference in their entirety.